Breast density in women with premature ovarian failure or postmenopausal women using hormone therapy
analytical cross-sectional study
Keywords:
Hormone replacement therapy, Mammography, Menopause, Premature ovarian failure, BreastAbstract
CONTEXT AND OBJECTIVE: Studies on postmenopausal women have reported increased risk of breast cancer relating to the type and duration of hormone therapy (HT) used. Women with premature ovarian failure (POF) represent a challenge, since they require prolonged HT. Little is known about the impact of prolonged HT use on these women’s breasts. This study aimed to evaluate the effects of one type of HT on the breast density of women with POF, compared with postmenopausal women. DESIGN AND SETTING: Cross-sectional study at the Department of Obstetrics and Gynecology, Universidade Estadual de Campinas (Unicamp). METHODS: 31 women with POF and 31 postmenopausal women, all using HT consisting of conjugated equine estrogen combined with medroxyprogesterone acetate, and matched according to HT duration, were studied. Mammography was performed on all subjects and was analyzed by means of digitization or Wolfe’s classification, stratified into two categories: non-dense (N1 and P1 patterns) and dense (P2 and Dy). RESULTS: No significant difference in breast density was found between the two groups through digitization or Wolfe’s classification. From digitization, the mean breast density was 24.1% ± 14.6 and 18.1% ± 17.2 in the POF and postmenopausal groups, respectively (P = 0.15). Wolfe’s classification identified dense breasts in 51.6% and 29.0%, respectively (P = 0.171). CONCLUSION: There was no difference in breast density between the women with POF and postmenopausal women, who had used HT for the same length of time. These results may help towards compliance with HT use among women with POF.
Downloads
References
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement the- rapy in the Million Women Study. Lancet. 2003;362(9382):419-27.
Conner P, Svane G, Azavedo E, et al. Mammographic breast density, hormones, and growth factors during continuous combined hormone therapy. Fertil Steril. 2004;81(6):1617-23.
Chen FP, Cheung YC, Teng LF, Soong YK. The relationship between mammographic density and duration of hormone therapy: effects of estrogen and estrogen-progestin. Hum Reprod. 2005;20(6):1741-5.
Harvey J, Scheurer C, Kawakami FT, et al. Hormone replacement therapy and breast density changes. Climacteric. 2005;8(2):185-92.
Junkermann H, von Holst T, Lang E, Rakov V. Influence of different HRT regimens on mammo- graphic density. Maturitas. 2005;50(2):105-10.
Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, et al. The effect of low dose hormone therapy on mammographic breast density. Maturitas. 2006;54(1):78-85.
Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and accuracy of mam- mographic screening. Lancet. 2000;355(9200):270-4.
Banks E. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen. 2001;8(1):29-34.
Warren R. Hormones and mammographic breast density. Maturitas. 2004;49(1):67-78.
Armitage M, Nooney J, Evans S. Recent concerns surrounding HRT. Clin Endocrinol (Oxf). 2003;59(2):145-55.
Mann RD. Hormone replacement therapy and breast cancer risk: studies of the last fifteen years. In: Mann RD, editor. Hormone replacement therapy and breast cancer risk. New Jer- sey: Parthenon Publishing Group; 1992. p. 1-8.
Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995;87(9):670-5.
Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995;87(21):1622-9.
Maskarinec G, Meng L. A case-control study of mammographic densities in Hawaii. Breast Cancer Res Treat. 2000;63(2):153-61.
Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control. 2000;11(7):653-62.
Noh JJ, Maskarinec G, Pagano I, Cheung LW, Stanczyk FZ. Mammographic densities and circula- ting hormones: a cross-sectional study in premenopausal women. Breast. 2006;15(1):20-8.
Laya MB, Gallagher JC, Schreiman JS, et al. Effect of postmenopausal hormonal re- placement therapy on mammographic density and parenchymal pattern. Radiology. 1995;196(2):433-7.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047-59.
Marugg RC, van der Mooren MJ, Hendriks JH, Rolland R, Ruijs SH. Mammographic changes in postmenopausal women on hormonal replacement therapy. Eur Radiol. 1997;7(5):749-55.
Koukoulis GN. Hormone replacement therapy and breast cancer risk. Ann N Y Acad Sci. 2000;900:422-8.
Lundström E, Wilczek B, von Palffy Z, Söderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unoppo- sed transdermal and low-potency estrogen regimens. Climacteric. 2001;4(1):42-8.
Greendale GA, Palla SL, Ursin G, et al. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmeno- pausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol. 2005;162(9):826-34.
de Moraes-Ruehsen M, Jones GS. Premature ovarian failure. Fertil Steril. 1967;18(4):440- 61.
Cymberknoh M. Mamografia digital. In: Dias EN, Caleffi M, Silva HMS, Figueira-Filho ASS, eds. Mastologia atual. Rio de Janeiro: Revinter; 1994. p. 75-8.
Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roent- genol. 1976;126(6):1130-7.
Snedecor WG, Cochram WG. The comparison of two samples. In: Snedecor WG, Cochram WG, editors. Statistical methods. 8thed Ames: Iowa State University Press; 1989. p. 83- 102.
Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regi- mens on mammographic breast parenchymal density. J Clin Oncol. 1997;15(10):3201-7.
Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: rela- tionship with breast cancer risk. Radiology. 2004;230(1):29-41.
